Last reviewed 2026-05-14 · How we verify

MabThera infusions

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Tachycardia
• Fatigue
• Pyrexia
• Infusion Related Reaction
• Headache
• Bronchitis
• Nasopharyngitis
• Rhinitis

Key clinical trials

• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
• CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
• Rituximab for Anti-cytokine Autoantibody-Associated Diseases (PHASE1)
• A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
• Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MabThera infusions CI brief — competitive landscape report
• MabThera infusions updates RSS · CI watch RSS
• Teva Pharmaceutical Industries, Ltd. portfolio CI